At the news
? BULLISHIMPACT 7/10 8-K filed Jul 13, 2026 at 08:37 ET
Edgewise Therapeutics completed the sale of its sevasemten muscular dystrophy program to Servier for $1.55 billion in upfront cash and up to $1.1 billion in milestones, for total potential consideration of up to $2.65 billion. The transaction transforms Edgewise into a cardiovascular-focused company and is expected to fully fund EDG-7500 development through potential approval. The closing removes deal risk and provides a strong cash runway.
- Edgewise received $1.55 billion in upfront cash from Servier for the sevasemten program.
- Up to $1.1 billion in additional regulatory and commercial milestones, for aggregate potential consideration of up to $2.65 billion.
- Transaction closed on July 10, 2026, as previously announced on June 1, 2026.
- Company is now a cardiovascular-focused biopharma with pipeline including EDG-7500, EDG-15400, and EDG-003.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access